What 50/50 Can Teach Us About Soft Tissue Sarcoma

What the film shows

50/50 came out in 2011. Joseph Gordon-Levitt plays Adam, a man in his twenties who goes to a doctor with back pain and comes out with a cancer diagnosis. The screenplay is loosely based on the real experience of its writer, Will Reiser.

A Macmillan cancer support specialist reviewed the film for The Guardian. She described Adam's diagnosis as a very rare nerve sheath tumor, a schwannoma. She had never met one in her own work. She had also never met a consultant like the one on screen, who gives Adam the news without looking at him.

Both parts of that reaction are useful. The rarity is real. The bedside manner is a plot device.

Nerve sheath tumors, and a word about the film's terminology

Nerves are wrapped in a protective layer, the sheath. Tumors can grow from the cells that make up that wrapping.

Most of those tumors are not cancer. Schwann cells build the sheath around nerves outside the brain and spinal cord. A schwannoma grows from them, and it is usually benign. The cancerous version has its own name: malignant peripheral nerve sheath tumor. NCI counts it as one type within soft tissue sarcoma. It even lists a set regimen for it, ifosfamide with etoposide.

Films compress. The exact words spoken on screen do not match how a pathology report would read. What the story gets right is the category: a cancer of the connective and supporting tissue rather than of an organ.

What "soft tissue sarcoma" actually covers

NCI defines soft tissue sarcoma as a broad term for cancers starting in soft tissues — muscle, tendons, fat, lymph and blood vessels, and nerves.

Those tissues run everywhere, so these cancers can start almost anywhere. NCI's clinical summary gives the split in adults. Forty-five percent start in the arms or legs. Thirty-eight percent start inside the abdomen. Ten percent are in the trunk and 5% in the head and neck.

It is a family, not a disease. NCI describes soft tissue sarcomas as a varied group of tumors that may arise in nearly any organ system, and treatment differs by subtype.

How rare, and how it is found

The American Cancer Society projects about 13,910 new soft tissue cancer diagnoses in the United States in 2026 and about 5,400 deaths, figures SEER, NCI's cancer surveillance program, carries. Median age at diagnosis, which SEER measures itself, is 63, which makes Adam's age unusual rather than typical.

NCI notes that most soft tissue sarcomas are sporadic. That means they appear with no cause anyone can point to. The risk list is short. It holds past radiation therapy and long-standing lymphedema. It holds contact with thorium dioxide, vinyl chloride or arsenic. And it holds HIV plus human herpesvirus 8, in the case of Kaposi sarcoma.

Diagnosis runs through tissue. NCI advises a core-needle biopsy guided by imaging. In some cases a planned open biopsy is used instead. Either way, a pathologist who knows sarcomas should read it. NCI also stresses that the surgeon, radiation oncologist and radiologist should plan that first biopsy together. A badly placed needle track can spoil the operation that follows.

Imaging before any treatment may include plain x-ray, CT, MRI, and sometimes a PET scan.

When to get checked

There is no screening test. NCI states plainly that it has no evidence-based information on screening for soft tissue sarcoma, and none on preventing it. That is not an oversight; it is the honest position for a rare cancer with no known population-level risk factor.

So the useful signal is a lump, and the rules of thumb are about size and behavior:

• A soft tissue lump larger than about 5 cm, roughly the width of a golf ball
• A lump that is getting bigger rather than staying the same
• A lump that sits deep, beneath the muscle layer, rather than just under the skin
• A lump that is painful, or one that returns after being removed

Most lumps are lipomas or cysts and are not cancer. But a growing deep lump in a limb deserves an appointment and, if there is doubt, an MRI rather than a wait-and-see.

What treatment involves

NCI's clinical summary is direct about the best case: small, low-grade tumors, particularly in the trunk or limbs, are frequently cured by surgery alone.

Surgical margins matter a great deal. A positive margin means cancer cells reach the cut edge. NCI lists that among the poor prognostic factors. So are age over 60, a tumor larger than 5 cm, a high grade under the microscope, and an advanced stage at diagnosis.

For advanced or spread disease, a class called anthracyclines still comes first. NCI lists later options too: gemcitabine with docetaxel, ifosfamide, trabectedin, eribulin, pazopanib and dacarbazine. Our page on chemotherapy covers what those drugs involve.

Follow-up is watchful. NCI cites a review in which more than 80% of relapses occurred within the first two years, and notes that some subtypes recur later than five years.

The survival picture

SEER reports five-year relative survival of 83.3% for soft tissue cancer found while confined to where it started, which is 57% of cases. For the 18% that have reached nearby lymph nodes it is 58.2%, and for the 17% found after distant spread, 17.0%. Across all stages the figure is 65.7% for people diagnosed from 2016 through 2022.

These are averages across a whole registry. They also pool dozens of different subtypes together. They describe a group, not a person. For a family of diseases this varied, they are a rough guide at best.

What this does not mean

The title refers to Adam being told he has a 50/50 chance. That number belongs to a script. A real estimate rests on subtype, grade, size, stage and margins. No film can show those.

The story also compresses treatment into a few scenes. Our overview of cancer treatment sets out the real sequence, and what cancer is covers the underlying biology.

And a rare diagnosis in a young character makes for a strong film precisely because it is unrepresentative. The median age of 63 is the more ordinary reality.

Sources

• The Guardian: Cancer support specialist Niki McCloud on 50/50
• The Guardian: 50/50 — review
• NCI PDQ: Soft Tissue Sarcoma Treatment (Health Professional Version)
• NCI: Soft Tissue Sarcoma—Patient Version
• NCI SEER Stat Facts: Soft Tissue Cancer including Heart

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

See an error, old source, or unclear wording? Tell us.